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Is sleep apnoea syndrome a cardiovascular disease?
Le syndrome d’apnée du sommeil est-il une pathologie cardiovasculaire ?
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Sleep apnoea syndrome (SAS) has become a common disorder with a potential deleterious
impact on the cardiovascular system. The prevalence varies from 4 to 14% depending on
a number of factors including age (increased prevalence after the age of 50), sex (more
common in men), body mass index (BMI; more prevalent in obese individuals), deﬁnitions
(apnoea-hyperpnoea index per hour) and regions of the world (more common in North
America than in Europe) [1,2]. Obstructive sleep apnoea (OSA) occurs more frequently in
obese patients and is present in a large proportion of patients with hypertension, coronary
artery disease, stroke and atrial ﬁbrillation [3]. In contrast, central sleep apnoea (CSA)
occurs mainly in patients with severe heart failure [4].
Repetitive apnoeas expose the cardiovascular system to cycles of hypoxia and exag-
gerate negative intrathoracic pressure and arousal. These deleterious stimuli can depress
myocardial wall stress and parasympathetic activity, provoke oxidative stress and activate
systemic inﬂammation, and impair vascular endothelial function [3]. Negative intratho-
racic pressure increases right ventricular preload while apnoea-induced hypoxia causes
pulmonary vasoconstriction, thus increasing right ventricular afterload. This could impede
left ventricular ﬁlling and decrease stroke volume. Hypoxia during OSA might also directly
impair cardiac contractility and diastolic relaxation [3].In this issue, Paulino et al. [5] reported the high prevalence of SAS (80%) in a large
cohort of patients with chronic heart failure (CHF) (n = 316). The authors emphasized the
high prevalence of severe SAS (≥ 30/h) (41% of the patients with SAS). In line with the
literature, patients with SAS were more frequently male, older, with a higher preva-
lence of atrial ﬁbrillation, and a higher brain-natriuretic peptide (BNP) concentration
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nd BMI compared to patients without SAS. However, left
entricular ejection fraction (LVEF) and functional class of
eart failure did not differ signiﬁcantly between the two
roups. They also reported that in the SAS group, OSA was
ore frequent (70%) than CSA (30%). CSA was associated
ith lower LVEF, higher BNP concentration and prevalence of
trial ﬁbrillation compared with OSA and non-SAS patients.
t is of note that the prevalence of SAS in this French study
s higher than in other studies (60 to 75%) despite using the
ame deﬁnition for SAS and severity of heart failure [6,7].
gain, the higher prevalence of OSA compared with CSA has
ot been reported before in CHF (usually a similar or a pre-
ominance of CSA is reported) [8]. This discrepancy could be
ue to the ability of beta-blockers and biventricular pacing
o reduce the risk of CSA [6].
OSA has been identiﬁed as a possible independent risk
actor for the development of heart and vascular disease,
hile CSA is rather a consequence of cardiovascular dis-
ase. Meanwhile, the pathophysiology of CSA has not been
lucidated. Whether CSA is an epiphenomenon in CHF or
ould lead to an increased risk or progression of heart failure
emains a matter of debate. However, it is well established
hat CSA is associated with a poor outcome in CHF [9,10].
Clinical and experimental studies argue for a close rela-
ion between sleep apnoea and cardiovascular disease [4,6].
leep apnoea could initiate cardiovascular disease and/or
ccelerate disease progression in patients with established
ardiovascular disease. The clinical question is how to diag-
ose SAS in CHF patients and why? Patients with CHF should
ndergo dual management involving both cardiologists and
hysicians involved in sleep apnoea through a network or
specialized in- or outpatient clinic. SAS should be inves-
igated in patients with CHF. Clinical trials evaluating the
mpact and consequences of SAS on cardiovascular disease
re still to be performed [11,12]. Furthermore, we have to
ove into the era of treatment strategies for SAS (e.g., con-
inuous positive airway pressure [CPAP] or positive airway
ressure, mandibular advancement appliances or new drugs
ith a central nervous effect on sleep apnoea) and evalu-
te whether these treatments could improve cardiovascular
isease by reducing cardiovascular morbidity and mortal-
ty. CPAP has already demonstrated acute and long-term
eneﬁts in terms of left ventricular function but with no
ong-term beneﬁt on clinical outcome [13—17]. Finally, the
ffect of heart failure therapies on CSA (e.g., beta-blockers,
enin angiotensin system blockers, cardiac resynchroniza-
ion) should be also investigated.eferences
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